Foundayo vs Zepbound: pill or injection?
The short answer
Foundayo vs Zepbound is a choice between a once-daily tablet and a once-weekly injection. Foundayo (orforglipron) and Zepbound (tirzepatide) are both FDA-approved for long-term weight reduction in adults, and Zepbound also for obstructive sleep apnea. LillyDirect self-pay runs $149 to $299 a month for Foundayo and $299 to $449 for Zepbound vials or KwikPen with on-time refills.
Key takeaways
- Foundayo isn't a pill version of Zepbound. They're different molecules with separate labels, dose ladders and prices.
- Only Zepbound is approved for moderate to severe obstructive sleep apnea, in adults with obesity.
- Paying cash through LillyDirect? Foundayo tops out at $299 a month and Zepbound vials or KwikPen at $449, with on-time refills.
- On LillyDirect, refill within 45 days to keep the price: Foundayo from 14.5 mg, Zepbound from 7.5 mg.
- On Medicare, the GLP-1 Bridge covers Foundayo tablets but only the KwikPen form of Zepbound, for people who qualify.
Foundayo vs Zepbound, side by side
| Foundayo | Zepbound | |
|---|---|---|
| Active ingredient | orforglipron | tirzepatide |
| Maker | Eli Lilly and Company | Eli Lilly and Company |
| FDA-approved uses |
|
|
| How it is taken | daily (tablet) | weekly (multi-dose pen); weekly (multi-dose vial); weekly (single-dose pen); weekly (single-dose vial) |
| Strengths | 0.8 to 17.2 mg | 2.5 to 15 mg |
| Label starting dose |
|
|
| Cheapest verified self-pay | $299 per fill at 17.2 mg | $449 per fill at 15 mg |
| With covering commercial insurance | $25 with the manufacturer card | $25 with the manufacturer card |
| Medicare GLP-1 Bridge | Yes: Tablet (once daily) | Yes: KwikPen (multi-dose, 4 weekly doses) |
| Label | Revised: 7/2026 (DailyMed version 10) | Revised: 8/2026 (DailyMed version 40) |
| Reaction | 17.2 mg | Placebo |
|---|---|---|
| Nausea | 35% | 10% |
| Diarrhea | 25% | 11% |
| Constipation | 24% | 9% |
| Vomiting | 24% | 4% |
| Abdominal pain | 14% | 7% |
| Dyspepsia | 13% | 4% |
| Reaction | 15 mg | Placebo |
|---|---|---|
| Nausea | 28% | 8% |
| Diarrhea | 23% | 8% |
| Vomiting | 13% | 2% |
| Constipation | 11% | 5% |
| Abdominal Pain | 10% | 5% |
| Dyspepsia | 10% | 4% |
Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.
Foundayo and Zepbound both come from Eli Lilly, both are approved for long-term weight reduction in adults, and both are sold to cash-paying patients through LillyDirect. Past that, they have little in common. Foundayo is orforglipron, a tablet you take every day. Zepbound is tirzepatide, an injection you give once a week.
Which one suits whom?
- You don’t want to inject. Foundayo is a tablet, taken once daily with or without food.
- You’d rather deal with it once a week. Zepbound is a weekly injection, by single-dose vial, KwikPen or single-dose pen.
- You have moderate to severe obstructive sleep apnea with obesity. That use is on the Zepbound label. Foundayo’s only approved use is weight reduction.
- You’re paying cash. Foundayo’s self-pay price is lower than Zepbound’s at every step of the ladder.
- You’re on Medicare. Both are in the Bridge, but only the KwikPen form of Zepbound is.
Is Foundayo as effective as Zepbound? Neither label can tell you, because each reports its own trials. What you can go through with your prescriber is whether the sleep apnea use applies to you, what’s on your medicine list, and whether a daily pill or a weekly injection fits your life.
What is each one approved for?
Both are approved to reduce excess body weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related condition. Both labels say to use the medicine with a reduced-calorie diet and increased physical activity.
Zepbound has a second approved use: moderate to severe obstructive sleep apnea in adults with obesity. Foundayo doesn’t.
The two aren’t combined. The Foundayo label says use with another GLP-1 receptor agonist isn’t recommended, and the Zepbound label says the same of any GLP-1 receptor agonist.
How is each one taken?
Foundayo. One tablet by mouth once daily, with or without food, swallowed whole, and no more than one a day. Strengths are 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg. The label starts at 0.8 mg, moves to 2.5 mg after at least 30 days and then to 5.5 mg after at least 30 more. Further steps to 9 mg, 14.5 mg and 17.2 mg are optional, each after at least 30 days, based on response and tolerability. A fill is a bottle of 30 tablets, kept at room temperature.
Zepbound. One injection once weekly, at any time of day, with or without meals, under the skin of the abdomen or thigh (or the back of the upper arm when someone else gives it). Strengths are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The label starts at 2.5 mg for 4 weeks, moves to 5 mg, and allows 2.5 mg increases after at least 4 weeks on each dose, up to 15 mg. The 2.5 mg dose is for starting only. The maintenance dose (the dose you stay on) for weight reduction is 5 mg, 10 mg or 15 mg. A fill is 28 days. Single-dose pens and vials are stored in the refrigerator and can be kept unrefrigerated at up to 86°F for a total of 21 days.
Here’s where the labels differ:
- Birth control pills. Both labels advise people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method after starting and after each dose increase: for 30 days with Foundayo, for 4 weeks with Zepbound.
- Interacting medicines and the liver. With a strong CYP3A4 inhibitor (a type of medicine that slows how the body clears some drugs), the maximum Foundayo dosage is 9 mg once daily. Foundayo isn’t recommended in severe liver impairment. Ask your pharmacist to check your medicine list.
- Supplies. Zepbound vials need a syringe and needle for every injection, and the KwikPen needs pen needles, bought separately. Foundayo needs nothing but the bottle.
The dosing guide and the titration schedule tool lay out both ladders, and the pen vs vial vs pill comparer compares the forms on cost.
What does each label report on weight?
Each label reports its own drug against placebo.
- Foundayo, Trial 1 (adults without diabetes, 72 weeks): mean (average) body-weight change of -7.4% with 5.5 mg, -8.3% with 9 mg and -11.1% with 17.2 mg, versus -2.1% with placebo. The label states that these trials used an investigational orforglipron formulation (a study version, not the tablet sold today), presented as equivalent once-daily Foundayo dosages.
- Zepbound, Study 1 (adults without diabetes, assessed after 72 weeks): -15.0% with 5 mg, -19.5% with 10 mg and -20.9% with 15 mg, versus -3.1% with placebo.
The trial lengths happen to match. But these are two separate programs with their own participants and dose schedules, and one used a formulation other than the marketed tablet. They aren’t a head-to-head result, and we draw no ranking from them. They’re averages for a trial group, not a forecast for you.
What does each one cost?
Both are priced by strength on LillyDirect:
Foundayo. $149 a month for 0.8 mg and for 2.5 mg, $199 for 5.5 mg, and $299 for 9 mg, 14.5 mg and 17.2 mg. The list price (the full price before any discount) is $649 a month.
Zepbound vial or KwikPen. $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg. The single-dose pen has no self-pay program price and lists at $1,086.37 per fill.
The refill window. Both drugs tie their higher-strength prices to refilling within 45 days of getting the last fill. For Foundayo this applies to 14.5 mg and 17.2 mg, where a late refill costs $349. For Zepbound it applies from 7.5 mg, where a late refill costs $499 at 7.5 mg and $699 at 10 mg and above. At 10 mg and above, the increase for a late Zepbound refill is the larger of the two. The 45-day rule page explains how the window is counted.
Savings cards. With commercial insurance that covers the drug, the card brings Foundayo to as little as $25 and the Zepbound single-dose pen to as little as $25.
A year. Starting at the lowest dose and stepping up on the label’s schedule with on-time refills, your first year comes to $3,188 for Foundayo to 17.2 mg and $5,637 for Zepbound vials to 15 mg.
The Foundayo cost and Zepbound cost pages rank each route, and the cost calculator totals any dose path.
How do insurance and Medicare treat them?
Commercial plans. Both sit under weight-management benefits, which some employers exclude. Where the class is covered, a plan may list one, both or neither, usually with prior authorization (the plan’s approval before it pays). Zepbound’s sleep apnea use gives it a second basis for a coverage request that Foundayo doesn’t have. Ask your plan about each brand by name. See the insurance guide.
Medicare. The Part D statute excludes drugs when used for weight loss. The Medicare GLP-1 Bridge is the temporary route for weight management, and it lists both: Foundayo tablets and the Zepbound KwikPen, each at a $50 copay for those who qualify. Zepbound single-dose vials and single-dose pens aren’t Bridge products. Outside the Bridge, CMS names Zepbound for moderate to severe obstructive sleep apnea in adults with obesity as a use coverable under Part D. See does Medicare cover Zepbound.
How do the side effects compare?
Both labels carry a boxed warning headed “Risk of Thyroid C-Cell Tumors,” and both report mostly gastrointestinal (stomach and bowel) reactions. Each table below is that drug’s own pooled trials, both of up to 72 weeks in adults with obesity or overweight. They’re still separate programs, so the rates describe each medicine and don’t rank them.
Foundayo. Nausea was reported by 26, 34 and 35 percent of patients on 5.5 mg, 9 mg and 17.2 mg, against 10 percent on placebo. Diarrhea was reported by 21, 23 and 25 percent (placebo 11 percent), vomiting by 13, 21 and 24 percent (placebo 4 percent) and constipation by 20, 27 and 24 percent (placebo 9 percent). Across both trials, 8% of patients on Foundayo permanently stopped treatment because of adverse reactions, compared with 3% on placebo.
Zepbound. Nausea was reported by 25, 29 and 28 percent of patients on 5 mg, 10 mg and 15 mg, against 8 percent on placebo. Diarrhea was reported by 19, 21 and 23 percent (placebo 8 percent), vomiting by 8, 11 and 13 percent (placebo 2 percent) and constipation by 17, 14 and 11 percent (placebo 5 percent). Injection site reactions, which a tablet can’t cause, were reported by 6, 8 and 8 percent against 2 percent. Across both trials, 4.8%, 6.3% and 6.7% of patients on the three doses permanently stopped treatment because of adverse reactions, compared with 3.4% on placebo.
Both labels say nausea, vomiting and diarrhea were more common during dose escalation, while the dose was going up, and decreased over time. The side effects guide covers the warnings.
Switching between Foundayo and Zepbound
Neither label describes a move to it from another GLP-1 medicine. The Foundayo label gives only its starting dose of 0.8 mg once daily. The Zepbound label gives only its starting dose of 2.5 mg once weekly. No label matches a strength of one to a strength of the other, and we don’t offer a conversion.
A switch needs a new prescription, and your prescriber decides the starting dose and the timing. The switching guide sets out what each label says, and the switching planner compares the monthly cost before and after.
Frequently asked questions
Is Foundayo the pill version of Zepbound?
No. Both are made by Eli Lilly and both are approved for weight reduction, but they contain different molecules. Foundayo is orforglipron, a tablet taken once daily. Zepbound is tirzepatide, an injection given once weekly. Each has its own label, dose ladder and prices.
Is Foundayo cheaper than Zepbound?
On LillyDirect self-pay, yes at every step. Foundayo is $149 a month at the two lowest strengths, $199 at 5.5 mg and $299 from 9 mg up. Zepbound vials or KwikPen are $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg up. Both depend on on-time refills at their higher strengths.
Does Zepbound work better than Foundayo?
The labels can't tell you. Each reports 72-week placebo-controlled trials of its own drug, and the Foundayo label notes its data come from an investigational formulation. Results from separate trials, with separate participants, can't be compared as if they were one study.
Can I switch from Zepbound to Foundayo?
Your prescriber can change the prescription, but the Foundayo label gives no instructions for switching from another GLP-1 medicine. It gives only its starting dose, 0.8 mg once daily. No label converts a Zepbound dose into a Foundayo dose. Both labels say the medicines shouldn't be combined with another GLP-1 receptor agonist, so they aren't taken together.
Does the Medicare GLP-1 Bridge cover Foundayo and Zepbound?
Yes, both, at a $50 copay for a one-month supply for people who meet the criteria. The form makes a difference, though. The Bridge covers Foundayo tablets, but for Zepbound it covers the KwikPen only, not single-dose vials or single-dose pens. Part D can separately cover Zepbound for obstructive sleep apnea.
Does the 45-day refill rule apply to Foundayo?
At its two highest strengths, yes. For Foundayo 14.5 mg and 17.2 mg, the LillyDirect price of $299 applies when you refill within 45 days. After that, it's $349. For Zepbound the rule starts at 7.5 mg, and a late refill of 10 mg or more costs $699.
Sources (37)
- 1.FDA label (DailyMed): Foundayo prescribing information, section 2.1
“Take FOUNDAYO orally once daily, with or without food.”
- 2.FDA label (DailyMed): Foundayo prescribing information, section 2.1
“Swallow tablets whole. Do not break, crush, or chew.”
- 3.FDA label (DailyMed): Foundayo prescribing information, section 2.1
“Do not take more than one tablet per day.”
- 4.FDA label (DailyMed): Foundayo prescribing information, section 2.1
“The starting dosage is 0.8 mg orally once daily. After at least 30 days on the 0.8 mg dosage, increase the dosage to 2.5 mg once daily.”
- 5.FDA label (DailyMed): Foundayo prescribing information, section 2.1
“The maximum dosage of FOUNDAYO is 17.2 mg once daily.”
- 6.FDA label (DailyMed): Foundayo prescribing information, section 1
“Concomitant use with another GLP-1 receptor agonist is not recommended.”
- 7.FDA label (DailyMed): Foundayo prescribing information, section 7.3
“Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation with FOUNDAYO and for 30 days after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected.”
- 8.FDA label (DailyMed): Foundayo prescribing information, section 2.2
“The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].”
- 9.FDA label (DailyMed): Foundayo prescribing information, section 8.6
“FOUNDAYO is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C) [see Clinical Pharmacology (12.3)].”
- 10.FDA label (DailyMed): Foundayo prescribing information, section 16.2
“Store FOUNDAYO at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature].”
- 11.FDA label (DailyMed): Foundayo prescribing information, section 14
“In these trials, the primary efficacy parameter was mean percent change in body weight after 72 weeks of treatment.”
- 12.FDA label (DailyMed): Foundayo prescribing information, section 14
“This section of labeling presents efficacy data from administration of the investigational orforglipron formulation shown as equivalent dosages of once daily FOUNDAYO [see Dosage and Administration (2.1)].”
- 13.FDA label (DailyMed): Foundayo prescribing information, section 14, Table 6
“Table 6: Changes from Baseline in Body Weight at Week 72 in Trials 1 and 2 in Patients with Obesity or Overweight with ≥1 Weight-related Comorbid Condition. % Change from baseline: Trial 1 Placebo once daily N = 949: -2.1; Trial 1 FOUNDAYO 5.5 mg once daily N = 723: -7.4; Trial 1 FOUNDAYO 9 mg once daily N = 725: -8.3; Trial 1 FOUNDAYO 17.2 mg once daily N = 730: -11.1; Trial 2 Placebo once daily N = 630: -2.5; Trial 2 FOUNDAYO 5.5 mg once daily N = 329: -5.1; Trial 2 FOUNDAYO 9 mg once daily N = 332: -7; Trial 2 FOUNDAYO 17.2 mg once daily N = 322: -9.6”
- 14.FDA label (DailyMed): Foundayo Medication Guide (in the prescribing information)
“Use FOUNDAYO with a reduced-calorie diet and increased physical activity.”
- 15.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Administer ZEPBOUND in combination with a reduced-calorie diet and increased physical activity.”
- 16.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Administer ZEPBOUND once weekly at any time of day, with or without meals.”
- 17.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm. Rotate injection sites with each dose.”
- 18.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Instruct patients using ZEPBOUND vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.”
- 19.FDA label (DailyMed): Zepbound prescribing information, section 2.2
“The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”
- 20.FDA label (DailyMed): Zepbound prescribing information, section 2.1
“The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”
- 21.FDA label (DailyMed): Zepbound prescribing information, section 8.3
“Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”
- 22.FDA label (DailyMed): Zepbound prescribing information, section 16.2
“Store ZEPBOUND single-dose pen and single-dose vial in a refrigerator at 2°C to 8°C (36°F to 46°F).”
- 23.FDA label (DailyMed): Zepbound prescribing information, section 16.2
“If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days. Discard single-dose pen and single-dose vial after a total of 21 days at room temperature.”
- 24.FDA label (DailyMed): Zepbound prescribing information, section 1
“ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
- 25.FDA label (DailyMed): Zepbound prescribing information, section 14.1
“In both trials, weight reduction was assessed after 72 weeks of treatment (at least 52 weeks at maintenance dose).”
- 26.FDA label (DailyMed): Zepbound prescribing information, section 14.1, Table 2
“Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight. % Change from baseline: Study 1 Placebo N = 643: -3.1; Study 1 ZEPBOUND 5 mg N = 630: -15.0; Study 1 ZEPBOUND 10 mg N = 636: -19.5; Study 1 ZEPBOUND 15 mg N = 630: -20.9; Study 2 Placebo N = 315: -3.2; Study 2 ZEPBOUND 10 mg N = 312: -12.8; Study 2 ZEPBOUND 15 mg N = 311: -14.7”
- 27.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
“The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
- 28.CMS: Information for Part D Plans
“Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
Related pages
- Foundayo (orforglipron): the once-daily weight loss pill
- What is Zepbound? Uses, cost, doses and side effects
- Foundayo cost: how much the pill is a month, by dose
- Zepbound cost: what you pay with and without insurance
- Tirzepatide vs semaglutide: how to compare Zepbound, Wegovy, Ozempic and the rest
- Cost calculator
